December 22, 2021
4 min watch
Save
VIDEO: ASH abstract broadens data on pacritinib impact in myelofibrosis
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
Aaron T. Gerds, MD, MS, speaks with Healio about results from a retrospective analysis of data from the Persist-2 study presented at ASH Annual Meeting and Exposition.
The data explored the impact of pacritinib on the symptoms of myelofibrosis among patients with moderate-to-severe thrombocytopenia.
“This was just a recut of data from these original trials that included a broader range of patients to really kind of hone in on spleen and symptom response,” said Gerds, assistant professor of medicine at Cleveland Clinic Taussig Cancer Institute and medical director of Case Comprehensive Cancer Center.
Reference
- Palmer JM, et al. Abstract 3628. Presented at: ASH Annual Meeting & Exposition; Dec. 11-14, 2021; Atlanta.
Published by:
Sources/Disclosures
Collapse
Source:
Healio Interview
Disclosures:
Gerds reports consulting for AbbVie, Bristol Myers Squibb, Constellation Pharmaceuticals, Novartis, PharmaEssentia and Sierra Oncology; and providing research support for Accurate Pharmaceuticals, Constellation Pharmaceuticals, CTI BioPharma, Imago BioSciences, Incyte Corporation and Kratos Pharmaceuticals.
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.